Caroline Seymour

CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib and bevacizumab, according to an analysis from the phase 3 PAOLA-1.

Richard S. Finn, MD, discusses the data with pembrolizumab and nivolumab that support their utility in hepatocellular carcinoma.

Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

Janakiraman Subramanian, MD, discusses the depth and durability of responses that have been reported with selpercatinib and pralsetinib, as well as ongoing research focused on improving outcomes and overcoming resistance mechanisms in RET fusion–positive NSCLC.

Aditya Bardia, MD, MPH, discusses the integration of ADCs and immunotherapy into the treatment landscape in metastatic TNBC and the future of AKT inhibitors in the field.

Lara A. Kujtan, MD, discusses the data that support the current utility of osimertinib in EGFR-mutant NSCLC and where else it is currently being explored.

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.

Cathy Eng, MD, FACP, FASCO, and Jordan D. Berlin, MD discuss pressing questions in hepatocellular carcinoma, colorectal cancer, gastric cancer, neuroendocrine tumors, and pancreatic cancer.

Olaparib and talazoparib failed to demonstrate statistically significant improvements in overall survival compared with chemotherapy in pretreated patients with BRCA1/2-mutant metastatic HER2-negative breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control

CDK4/6 inhibitors plus aromatase inhibitors have shown benefit as frontline treatment for patients with hormone receptor–positive, HER2-negative advanced breast cancer, but more data are needed to determine their role as adjuvant therapy before they are adopted into standard practice for patients with early-stage disease.

The KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB trials have changed practice for patients with HER2-positive breast cancer for the better.

Targeted DNA sequencing prior to transplant can be used to determine which patients with myelodysplastic syndrome are at high risk for posttransplant relapse and should forego reduced-intensity conditioning in lieu of myeloablative conditioning.

Darolutamide plus ADT will be evaluated versus ADT alone in patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARANOTE study as part Bayer and Orion Corporation’s growing clinical development program for the oral AR inhibitor in prostate cancer.

The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

Fixed-duration treatment that leads to deep treatment-free remissions has become the prioritized strategy for patients with chronic lymphocytic leukemia, made possible by agents such as venetoclax, umbralisib, and lisocabtagene maraleucel.

Gary J. Schiller, MD, discusses data from the 2020 ASH Annual Meeting and Exposition and the role of transplant in chronic myeloid leukemia.

Although chemotherapy remains the cornerstone of treatment in pancreatic ductal adenocarcinoma, the field has begun to carve out more personalized approaches evidenced by the POLO trial.

Christos Vaklavas, MD, discusses the progress that has been made in metastatic HR-positive, HER2-negative breast cancer and potential pathways forward for therapeutic sequencing.

Yi Lin, MD, PhD, discusses promising data with CAR T-cell therapy in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.

CAR T-cell therapy has shown robust responses and curative potential in patients with diffuse large B-cell lymphoma, regardless of cytogenetics or age.

Randy Stevens, MD, discusses the growing role for radiation in lung cancer, delivery techniques, and adverse effect management strategies.

February 11, 2021 - Sapanisertib failed to show significant activity and a favorable toxicity profile in patients with refractory metastatic renal cell carcinoma regardless of mTOR or PTEN status.

Mark A. Socinski, MD, discusses the nuances of the PACIFIC trial and ongoing research with durvalumab that could extend the reach of immunotherapy in early-stage lung cancer.

In the quest for scientific purity, one should not lose sight of the meaningful end points that can make a difference in patients’ daily lives.

Surgical resection should be a standard of care for patients with stage I to IIIA lung cancer, but probing for subclinical stage III disease with endobronchial ultrasound guided biopsy or mediastinoscopy to determine whether surgery should be performed prior to or after systemic therapy.